News
News
PublISHED ON
UpDATED ON
Sweden participates in clinical WHO study
Sweden is participating in a major clinical study conducted by WHO, aimed at testing a number of antiviral medicines on patients around the world who are being treated for COVID-19.
Because more than 100 countries are taking part in the WHO study Solidarity Trial, the patient base is large. This makes it quicker to see whether any of the preparations are effective, and can begin to be used to treat the disease.
The Swedish Government recently appointed Soo Aleman, Consultant Physician at the Karolinska University Hospital and Associate Professor at Karolinska Institutet, to be the national coordinator for the Swedish part of the study. The Swedish Research Council will fund Swedish participation, as soon as the investment is formalized in the regulatory letter.
“It is important for Sweden to be part of the international study. Patients in Sweden who have suffered severe COVID-19 can now get access to potentially effective medicines. In the long term we will obtain greater knowledge of what is effective, which will also benefit patients who are not part of the study,” says Jan-Ingvar Jönsson, Secretary General of the Scientific Council for Medicine and Health and Clinical Therapy Research at the Swedish Research Council.
About the studie Solidarity trial on WHO´s website External link.
RELATERAT INNEHÅLL
MORE WITHIN THE SAME SUBJECT AREA
-
News |
Published 31 March 2023
The ALF evaluation, which is published today, shows a positive development for the quality of Swedish clinical research. At the same time, there are areas for improvement in all ALF regions evaluated – for example, time for research is often de-prior...
-
Publication |
Published 27 February 2023
The Swedish Research Council’s research review in clinical thearpy research describes the current situation for the research and makes a forecast of the development during the next 5–10 years. The review also includes scientific and research policy r...
-
Article |
Published 25 January 2023
You will receive an automated email from Prisma once the reporting period has started.